PERJETA (pertuzumab)
TherapyGenentech
PERJETA (pertuzumab) from Genentech is a HER2-directed antibody used in combination with trastuzumab-based regimens.
Approvals
3
Indications
1
Biomarkers
1
Mapped tests
3
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and PERJETA. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where PERJETA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Breast Cancer Solid Tumor · Breast | ERBB2 (HER2)
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for PERJETA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering PERJETA for eligible patients.
Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
HER2 FISH pharmDx Kit
Dako Denmark A/S (Agilent Technologies, Inc.)
Method
FISH
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
HercepTest
Dako Denmark A/S (Agilent Technologies, Inc.)
Method
IHC
Specimen
Tissue (FFPE)
1 approvalView test profile →